loader image
Sunday, February 23, 2025
43.5 F
McAllen
We Welcome your Press Release
- Advertisement -

TEXAS ONCOLOGY–MCALLEN TO HOST PRESS CONFERENCE FOR OCT. 25 FUNDRAISER

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

7th Annual Walk, Run, and Ride Promotes Breast Cancer Awareness and Rallies Survivors

What:              Texas Oncology–McAllen and City Commissioner Veronica Vela Whitacre will host a press conference on Tuesday, Oct. 14 to discuss the upcoming Walk, Run, and Ride promoting breast cancer awareness.

                        The 7th edition of the event begins at 8 a.m., on Saturday, Oct. 25 at Texas Oncology–McAllen, located at 1901South Second Street. Registration for the 5k run; 2.5 or 4.5 mile walk; or 20, 40, or 60 mile bicycle rally is now open. Proceeds from the event benefit the Texas Oncology Foundation, Comfort House, Food Bank of the RGV, Infinite Love, and Aurora House. For more information or to register, visit TXOWalkRunRide.com.

- Advertisement -

When:              Tuesday, Oct. 14 –10 a.m.

Where:            Texas Oncology–McAllen, 1901 South Second Street, McAllen, Texas, 78503 

Who:               Alvaro Restrepo, M.D., medical oncologist at Texas Oncology–McAllen, and event chairman Veronica Vela Whitacre, McAllen city commissioner. Other Walk, Run, and Ride participants

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

UPDATE: Measles Outbreak

Mega Doctor News Mega Doctor News  As of February 18, 2025, the Texas...

DHR Health Celebrates 100th Ion Robotic-Assisted Bronchoscopy

DHR Health, a leader in healthcare serving the Rio Grande Valley, announced today that Dr. Federico Vallejo, pulmonologist, has successfully performed his 100th Ion robotic-assisted bronchoscopy.

DHR Health: Pioneering Alzheimer’s Treatment Breakthrough South of San Antonio

DHR Health, a leader in healthcare innovation, proudly announced today its groundbreaking achievement as the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved medication for the early treatment of Alzheimer’s disease. This milestone demonstrates their expertise and is a significant advancement in healthcare for the Rio Grande Valley.

FDA Approves First CRISPR Gene Therapy to Treat Sickle Cell Disease

Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
- Advertisement -
×